In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, ...

Ozempic is under clinical development by Novo Nordisk and currently in Phase III for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Oh, oh, oh, with Khloe Kardashian now chiming in, it seems everyone in Hollywood—including Jessica Simpson, Sophie Turner, ...